![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
RDEA806, a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor, Shows Positive Outcome in Treatment of Naive HIV Patients
|
|
|
Reported by Jules Levin, ICAAC/IDSA 25-28 October 2008 Washington, DC
G. Moyle, M. Boffito, Z. Shen, K. Manhard, B. Sheedy, V. Hingorani, M. Nguyen, T. Nguyen, B. Quart, L. Yeh, V. Ong
RDEA806 AUTHOR CONCLUSIONS
--Well tolerated with robust antiviral effect across all doses
--Tmax ranged from 2-6 hours, half-life ~9-12 hours
--Antiviral activity similar between 800 mg QD and 400 mg BID
--No significant induction of CYP3A4, indicating a low potential for drug interactions
--Significant reduction in uric acid across all doses, with no effect on the renal excretion of tenofovir.
--Phase 2b in antiretroviral treatment-naïves planned to begin this quarter
Preclinical Background
--RDEA806 is a potent (EC50wt= 3 nM), selective HIV NNRTI designed to maintain activity against the most common mutations observed with efavirenz (EC50K103N= 2.3 nM)
--High barrier to resistance
--Cytotoxicity selectivity index > 9,000
--Highly protein bound (~99.5%)
--Limited metabolism by CYP450 (none by 2B6) and no inhibition or induction of CYP450
--Completed animal reproduction studies have shown no evidence of teratogenicity or impairment of fertility
--Highly water soluble, allowing for preparation of easy to swallow tablets easy to swallow tablets
![sample-1.gif](../images/102808/sample-1.gif)
![prof-2.gif](../images/102808/prof-2.gif)
![load-3.gif](../images/102808/load-3.gif)
![folrmax-4.gif](../images/102808/folrmax-4.gif)
![cohort-5.gif](../images/102808/cohort-5.gif)
![cyp-6.gif](../images/102808/cyp-6.gif)
![acrid-7.gif](../images/102808/acrid-7.gif)
![teno-8.gif](../images/102808/teno-8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|